Navigation Links
Appeals Court Rules in Favor of Prometheus, Upholds the Patentability of Its Claims for Methods of Thiopurine Metabolite Testing
Date:9/17/2009

SAN DIEGO, Sept. 17 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced that the U.S. Court of Appeals for the Federal Circuit has ruled in favor of Prometheus in a dispute over the validity of its patents that cover the methods for a diagnostic test that enables physicians to optimize ongoing dosing of thiopurines to reach and maintain desired therapeutic levels (U.S. Patent Nos. 6,355,623 and 6,680,302).

The patents were challenged by Mayo Clinic and Mayo's medical laboratory division on several grounds. The Federal Court ruling not only reversed the judgment of the district court, but also remanded the case to the district court with express instructions to deny Mayo's motion for summary judgment, which alleged that the patents' claims did not describe patentable subject matter.

"This clear-cut ruling by the U.S. Court of Appeals for the Federal Circuit did not simply remand but completely reversed the judgment of the U.S. District Court," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "Prometheus is committed to developing and commercializing innovative diagnostics and other products to help physicians improve patient lives. As a key element in enabling this strategy, we have historically taken the strong position that we will vigorously defend any intellectual property rights that we own or license, and we will continue to do the same going forward."

PROMETHEUS(R) Thiopurine Metabolites helps keep patients' drug metabolite levels within an optimal therapeutic range, thereby increasing the probability of a positive response and potentially reducing the need for other medications. Thiopurine metabolites testing helps identify some of the reasons for treatment failure and monitor for potential toxicity before it occurs.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and intends to apply these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Appeals Court Affirms Patent Infringement Rulings Against Roches peg-EPO Product
2. Major Rollback of Pharmaceutical Bench Mark Prices Approved by Federal Court of Appeals, Hagens Berman Announces
3. The American Legion Appeals to Congress for Compassionate Treatment of Women Veterans
4. Providence Service Corporation Comments on U.S. Court of Appeals Decision to Uphold Federal Injunction Blocking Californias 10% Cut in Medi-Cal Payments
5. Federal Appeals Court Protects California Home Care Pay
6. Cosmetic surgery appeals to men, women with appearance-based rejection sensitivity
7. Appeals Court OKs Multimillion-Dollar Judgment for Dallas Doctor
8. Congress Appeals to Obama Administration, Thailand: Stop Hmong Returns to Laos
9. UNICEF Appeals for Funding to Urgently Assist Displaced Children and Women in Northwest Pakistan
10. LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception
11. U.S. Court of Appeals Affirms 2006 Lower Court Ruling That Tobacco Companies Committed Fraud for Five Decades and Lied About the Dangers of Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Regenerative Medicine Solutions ... Work employee satisfaction survey, earning them second place for Tampa’s Best Places to Work. ... , “This is a great accomplishment for our team,” says RMS Human Resources ...
(Date:4/29/2016)... Newport Beach, CA (PRWEB) , ... April 29, 2016 , ... ... Dr. Jane L. Frederick, Dr. Sanaz Ghazal, and Dr. Daniel A. Potter -- are ... the Society for Assisted Reproductive Technology (SART). In April, SART published the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. recently sent ... probiotics, Petbiotics ™, as they fondly call them. As animal lovers, they ... for their non-profit organizations. Animal rescues across the nation face huge hurdles rescuing ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... software, outsourced billing and coding services, and Deyta Analytics, recently announced the recipients ... the highest level of quality as measured from the caregiver’s point of view. ...
(Date:4/29/2016)... ... 2016 , ... Intellitec Solutions is pleased to announce the ... for one their long-term care clients. Working together with the clients staff, Intellitec ... management systems, and delivered a fully integrated accounting and business-management solution that helped ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , Schweiz, April 27, 2016 /PRNewswire/ ... des Sachs CEO Forums in Zürich gab ... ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung des ... eingesetzt wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie ... und Frankreich angeworben. STR001 wird während der ...
(Date:4/27/2016)... Transparency Market Research has published ... Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... skincare devices market was valued at US$ 7,255.8 Mn ... CAGR of 10.1% from 2015 to 2023 to reach ... full Skincare Devices Market (Treatment Device - LED Therapy Devices, ...
(Date:4/27/2016)... Shire plc (LSE: SHP, NASDAQ: SHPG ... will present at the Deutsche Bank 41st Annual Health Care ... May 04, 2016, 10:00 am EDT (15:00 BST). ... and Webcasts section of Shire,s Investor website at http://investors.shire.com/presentations-and-webcasts/ ... on this same website for approximately 90 days. ...
Breaking Medicine Technology: